Comparative Pharmacology
Head-to-head clinical analysis: NYSTATIN TRIAMCINOLONE ACETONIDE versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTATIN TRIAMCINOLONE ACETONIDE versus OTICAIR.
NYSTATIN-TRIAMCINOLONE ACETONIDE vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
Apply topically to affected area twice daily for 2-4 weeks.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
Nystatin: negligible systemic half-life due to lack of absorption. Triamcinolone acetonide: terminal half-life ~2-5 hours (mean ~3.5 h) after intravascular administration; prolonged in hepatic impairment.
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Nystatin: negligible systemic absorption; excreted unchanged in feces (~100%). Triamcinolone acetonide: metabolized hepatically; renal excretion of metabolites (~40%) and unchanged drug (<5%); fecal excretion (~60%).
Renal: 85% unchanged; biliary/fecal: 10%
Category D/X
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid